Mannion J D, Blood V, Bailey W, Bauer T L, Magno M G, DiMeo F, Epple A, Spinale F G
Department of Surgery, Thomas Jefferson University, Philadelphia, Pa 19107, USA.
J Thorac Cardiovasc Surg. 1996 Jan;111(1):19-28. doi: 10.1016/S0022-5223(96)70397-5.
Previous studies designed to determine whether latissimus cardiomyoplasty could be used to revascularize ischemic myocardium showed that after operation the latissimus was ischemic and had severely deteriorated. This study was undertaken to determine whether basic fibroblast growth factor, a potent angiogenic peptide, would improve the vascularity of the latissimus and enhance collateral formation between the muscle of the cardiomyoplasty and ischemic myocardium. In goats, myocardial ischemia was induced with an ameroid constrictor and cardiomyoplasty performed. The latissimus was continuously stimulated electrically at 2 Hz for 6 weeks and given four weekly bolus injections of human recombinant basic fibroblast growth factor (80 micrograms infused into the left subclavian artery). In eight animals, rates of regional blood flow were measured and both the heart and latissimus were evaluated histochemically. The latissimus blood flow rate was 0.114 +/- 0.029 ml/gm per minute, which was three times greater than that of historical controls (chronically stimulated latissimus cardiomyoplasty without basic fibroblast growth factor treatment; 0.042 +/- 0.007 ml/gm per minute, p < 0.05). Associated with the improved blood flow, there was significantly less evidence of skeletal muscle fiber dropout and muscle fibrosis in the animals treated with basic fibroblast growth factor. Latissimus-derived collateral flow to ischemic myocardium developed in five of the eight goats and averaged 0.288 +/- 0.075 ml/gm per minute. This flow was 42.8% +/- 15.7% (n = 5) of the flow required by normal myocardium (which was 0.728 +/- 0.095 ml/gm per minute). This value for latissimus-derived collateral blood flow was almost twice that of the historical controls (24.0% +/- 3.9%), but the increase did not achieve statistical significance (p = 0.08). These results hold the promise that basic fibroblast growth factor treatment might enhance the formation of extramyocardial collaterals to the heart and improve skeletal muscle function.
以往旨在确定背阔肌心肌成形术是否可用于使缺血心肌血管再生的研究表明,术后背阔肌出现缺血且严重恶化。本研究旨在确定碱性成纤维细胞生长因子(一种有效的血管生成肽)是否会改善背阔肌的血管分布,并增强心肌成形术的肌肉与缺血心肌之间的侧支形成。在山羊身上,用阿梅氏环扎器诱导心肌缺血并进行心肌成形术。背阔肌以2赫兹频率持续电刺激6周,并每周给予4次人重组碱性成纤维细胞生长因子大剂量注射(80微克注入左锁骨下动脉)。在8只动物中,测量局部血流速率,并对心脏和背阔肌进行组织化学评估。背阔肌血流速率为每分钟0.114±0.029毫升/克,是历史对照组(未用碱性成纤维细胞生长因子治疗的慢性刺激背阔肌心肌成形术;每分钟0.042±0.007毫升/克,p<0.05)的三倍。与血流改善相关的是,接受碱性成纤维细胞生长因子治疗的动物中,骨骼肌纤维丢失和肌肉纤维化的证据明显减少。8只山羊中有5只出现了背阔肌向缺血心肌的侧支血流,平均为每分钟0.288±0.075毫升/克。该血流为正常心肌所需血流(每分钟0.728±0.095毫升/克)的42.8%±15.7%(n=5)。背阔肌来源的侧支血流值几乎是历史对照组(24.0%±3.9%)的两倍,但增加未达到统计学意义(p=0.08)。这些结果表明,碱性成纤维细胞生长因子治疗有望增强心脏外心肌侧支的形成并改善骨骼肌功能。